EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Humanized anti‐ CD25 monoclonal antibody replaces methotrexate as acute graft‐versus‐host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation

Ao Zhang, Zhenli Huang, Ran Zhang iD, Ruowen Wei, Shan Jiang, Hongru Chen, Xiena Cao, Wei Shi, Linghui Xia iD, Yu Hu iD

British Journal of Haematology · 2025

DOI: 10.1111/bjh.19958 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Ao Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Graft vs Host Disease, Methotrexate, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Young Scientists Fund of the National Natural Science Foundation of China, National Natural Science Foundation of Hubei Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute graft‐versus‐host disease (aGVHD) significantly affects quality of life and outcomes in patients post‐haploidentical haematopoietic stem cell transplantation (haplo‐HSCT). Methotrexate (MTX) is commonly used to prevent aGVHD but can lead to complications like delayed haematological recovery and oral mucositis (OM). This study investigates the efficacy of anti‐CD25 monoclonal antibody (mAb) as a potential MTX alternative. Participants were divided into two cohorts: a single‐dose group (25 mg/day anti‐CD25 mAb with MTX) and a double‐dose group (50 mg/day anti‐CD25 mAb without MTX). The primary end‐point was the cumulative incidence (CI) of severe aGVHD by day 100. The double‐dose cohort demonstrated a significantly lower CI of total aGVHD (23.53% vs. 42.11%, p = 0.009) and grade 3–4 aGVHD (7.35% vs. 18.42%, p = 0.047). After inverse probability of treatment weighting adjustment, the adjusted HR of double‐dose compared with single‐dose cohort for total aGVHD was 0.47 (95% CI 0.26–0.86; p = 0.015), 0.42(95% CI 0.15–1.22; p = 0.110) for grade III–IV aGVHD, 0.45 (95% CI 0.26–0.77; p = 0.004) for total cGVHD and 0.36 (95% CI 0.18–0.72; p = 0.004) for the moderate to severe cGVHD. Additionally, this double‐dose regimen significantly reduced the incidence of oral mucositis and demonstrated lower rates of infections and haemorrhagic cystitis. These findings suggest that a double‐dose anti‐CD25 mAb regimen without MTX is a promising strategy for aGVHD prophylaxis in haplo‐HSCT (ChiCTR2200060184).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseMethotrexateHematopoietic Stem Cell TransplantationAntibodies, Monoclonal, HumanizedInterleukin-2 Receptor alpha SubunitHumansMaleFemaleAdultMiddle AgedAcute DiseaseAdolescentYoung AdultTransplantation, Haploidentical

Stichwörter der Autor:innen

aGVHD prophylaxisacute graft‐versus‐host diseaseanti‐CD25 monoclonal antibodyhaploidentical haematopoietic stem cell transplantationmethotrexate

Substanzen

MethotrexateAntibodies, Monoclonal, HumanizedInterleukin-2 Receptor alpha Subunit

Autor:innen und Institutionen

  • Institute of Hematology, Union Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Ran Zhang, Linghui Xia, Yu Hu

Förderung

  • National Natural Science Foundation of China
  • Young Scientists Fund of the National Natural Science Foundation of China
  • National Natural Science Foundation of Hubei Province, China
  • Natural Science Foundation for Young Scientists of Shanxi Province

Zitieren

APA

Zhang, A., Huang, Z., Zhang, R., Wei, R., Jiang, S., Chen, H., Cao, X., Shi, W., Xia, L., & Hu, Y. (2025). Humanized anti‐ CD25 monoclonal antibody replaces methotrexate as acute graft‐versus‐host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.19958

Vancouver

Zhang A, Huang Z, Zhang R, Wei R, Jiang S, Chen H, et al. Humanized anti‐ CD25 monoclonal antibody replaces methotrexate as acute graft‐versus‐host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. 2025. doi:10.1111/bjh.19958

BibTeX
@article{Zhang2025,
  author = {Zhang, Ao and Huang, Zhenli and Zhang, Ran and Wei, Ruowen and Jiang, Shan and Chen, Hongru and Cao, Xiena and Shi, Wei and Xia, Linghui and Hu, Yu},
  title = {Humanized anti‐ CD25 monoclonal antibody replaces methotrexate as acute graft‐versus‐host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.19958}
}
Kostenlos starten →